Sangamo Therapeutics (LTS:0R1D) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R1D Sangamo Therapeutics Inc LTS:0R1D
35 GF Score
Price $0.10
GF Value $0.19
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sangamo Therapeutics FFO per Share?

FFO per Share only applies to REITs.

LTS:0R1D
35GF Score
Sangamo Therapeutics Inc LTS:0R1D
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sangamo Therapeutics (LTS:0R1D) Overvalued in 2026?

Based on GuruFocus' analysis, Sangamo Therapeutics stock appears to be undervalued. The current stock price of $0.10 is trading 47.4% below its estimated GF Value™ of $0.19. GuruFocus considers Sangamo Therapeutics to be Possible Value Trap.

Key valuation signals for LTS:0R1D:

  • FFO per Share:
  • GF Value™: $0.19 vs. price of $0.10 (47.4% below fair value)
  • GF Score™: 35/100 with 5 warning signs

No single metric tells the full story. See the LTS:0R1D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sangamo Therapeutics Business Description

Other Exchanges SGMO:USAGBY:Germany
Address 501 Canal Boulevard, Richmond, CA, USA, 94804
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.
35GF Score

Get the complete analysis for LTS:0R1D

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price
$0.19
GF Value